Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

被引：15
|
作者：
Verstovsek, Srdan
Deeg, H. Joachim [3 ]
Odenike, Olatoyosi [4 ]
Zhu, Joy [5 ]
Kantarjian, Hagop [1 ]
Estrov, Zeev
Scott, Bart Lee [2 ]
Thomas, Deborah A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Fred Hutchinson Canc Res Ctr, Dept Clin Res, Seattle, WA 98104 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] S BIO, Global Clin Dev, Redwood City, CA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.3082.3082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1271 / 1271
页数：1
相关论文
共 50 条
  • [41] SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS: IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT
    Scherber, R.
    Dueck, A.
    Geyer, H.
    Kosiorek, H.
    Kiladjian, J. J.
    Slot, S.
    Zweegman, S.
    Boekhorst, P.
    Schouten, H.
    Sackmann, F.
    Fuentes, A.
    Hernandez-Maraver, D.
    Pahl, H.
    Stegelmann, F.
    Doehner, K.
    Bonatz, K.
    Reiter, A.
    Boyer, F.
    Etienne, G.
    Ianotto, J. C.
    Ranta, D.
    Roy, L.
    Cahn, J. Y.
    Harrison, C.
    Radia, D.
    Muxi, P.
    Maldonado, N.
    Besses, C.
    Cervantes, F.
    Johansson, P.
    Barosi, G.
    Vannucchi, A.
    Passamonti, F.
    Andreasson, B.
    Samuelsson, J.
    Birgegard, G.
    Sun, X.
    Xu, J.
    Zhang, P.
    Xu, Z.
    Barbui, T.
    Barbui, T.
    Senyak, Z.
    Grieshammer, M.
    Rambaldi, A.
    Ferrari, M.
    Lehmann, T.
    Mesa, R.
    HAEMATOLOGICA, 2016, 101 : 557 - 558
  • [42] Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia
    Cleary, Megan M.
    Thompson, Rhese
    Mahmood, Shawn
    Davare, Monika
    Kurtz, Steve
    Elferich, Johannes
    Shinde, Ujwal
    Druker, Brian J.
    Singer, Jack
    Agarwal, Anupriya
    BLOOD, 2015, 126 (23)
  • [43] TG101348: A dual-acting JAK2/FLT3 small molecule kinase inhibitor for the treatment of AML
    Tam, Betty
    Mak, Chi Ching
    Stoughton, Silvia
    Virata, Cyrus
    Lohse, Dan
    Hanna, Ehab
    Alomia, Marcela
    Jamieson, Catriona
    Doukas, John
    Noronha, Glenn
    Martin, Michael
    Soll, Richard
    Hood, John
    BLOOD, 2007, 110 (11) : 274A - 274A
  • [44] A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study
    Zhou, Yile
    Huang, Jian
    Wen, Bingbing
    Zhou, Hu
    Yang, Wei
    Fan, Lianlian
    Gong, Tiejun
    Gao, Sujun
    Jiao, Zongjiu
    Liu, Qingchi
    Zhao, Lidong
    Wu, Guocai
    Wu, Cuicui
    Wang, Jun
    Zhang, Jin
    Fu, Jiaping
    Sheng, Zengmei
    Zhu, Zunmin
    Lu, Jian
    Zhang, Yi
    Jin, Jie
    BLOOD, 2024, 144 : 1808 - 1809
  • [45] A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF)
    Gisslinger, H.
    Skrabs, C.
    Gisslinger, B.
    Schoder, R.
    Muellauer, L.
    Kralovics, R.
    HAEMATOLOGICA, 2013, 98 : 346 - 347
  • [46] Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms (Vol 12, 37, 2022)
    Hu, Mengshi
    Yang, Tao
    Yang, Linyu
    Niu, Lu
    Zhu, Jinbing
    Zhao, Ailin
    Shi, Mingsong
    Yuan, Xue
    Tang, Minghai
    Yang, Jianhong
    Pei, Heying
    Yang, Zhuang
    Chen, Qiang
    Ye, Haoyu
    Niu, Ting
    Chen, Lijuan
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [47] Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML
    Azhar, Mohammad
    Kincaid, Zachary
    Kesarwani, Meenu
    Menke, Jacob
    Schwieterman, Joshua
    Ansari, Sekhu
    Reaves, Angela
    Ahmed, Arhama
    Shehzad, Rammsha
    Khan, Areeba
    Syed, Nuha
    Amir, Noor
    Wunderlich, Mark
    Latif, Tahir
    Seibel, William
    Azam, Mohammad
    BLOOD ADVANCES, 2023, 7 (08) : 1460 - 1476
  • [48] A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Pardanani, Animesh D.
    Shah, Neil P.
    Sokol, Lubomir
    Wadleigh, Martha
    Gilliland, D. Gary
    List, Alan F.
    Tefferi, Ayalew
    Kantarjian, Hagop M.
    Bui, Lynne A.
    Clary, Douglas O.
    BLOOD, 2007, 110 (11) : 170A - 170A
  • [49] The nonclinical toxicology profile of pacritinib, a JAK2/FLT3 inhibitor with no dose-limiting clinical myelosuppression
    Watson, Rebecca
    Al-Fayoumi, Suliman
    CANCER RESEARCH, 2016, 76
  • [50] Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
    A Pardanani
    J Gotlib
    A W Roberts
    M Wadleigh
    S Sirhan
    J Kawashima
    J A Maltzman
    L Shao
    V Gupta
    A Tefferi
    Leukemia, 2018, 32 : 1034 - 1037
12345